Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a first of its kind study into the population and spread of tuberculosis-causing (TB) bacteria in Ho Chi Minh City, Thuong Thuong Nguyn and collegues at OUCRU Vietnam, Australia, UK and Singapore have found that more than half of cases can be attributed to one particular strain of the bacteria.

TB  MDR-TB  TB/HIV

Using state-of-the-art genomics technology, a Melbourne-led international collaboration, including researchers from OUCRU in Vietnam and Singapore, sequenced the DNA from bacteria isolated from the lungs of 1635 TB patients located in outpatient clinics in eight districts of Ho Chi Minh City. The findings, published in Nature Genetics this week, concluded that the strain of TB-causing bacteria known as the Beijing lineage, was responsible for 59 per cent of infections, and even more (75%) of those diagnosed in younger people.

TB is the leading cause of death globally from a single infectious agent – Mycobacterium tuberculosis – that typically affects the lungs, but can also infect other sites of the body. Multiple antibiotics are used to treat TB, however treatment is long (six months), and the emergence of drug-resistant bacteria is a considerable threat to global health.

Vietnam is one of the WHO High Burden Countries for TB and multi drug-resistant TB, and in 2016 there were an estimated 126,000 cases and 13,850 deaths in the South East Asian country. Co-lead Investigator of the study and a Senior Research Fellow, Dr Sarah Dunstan from the Peter Doherty Institute for Infection and Immunity (a joint venture of The University of Melbourne and The Royal Melbourne Hospital), said within the Beijing lineage they found a mutation, which likely bolsters the bacteria’s ability to spread. “Combating and managing TB spread requires new strategies to diagnose, treat and protect against emerging and evolving strains of the bacteria,” said Dr Dunstan. “Armed with an understanding of how the disease is spread in Ho Chi Minh City could allow more targeted local TB control, and this knowledge could potentially be applied to other settings given the Beijing lineage is found worldwide, predominantly in Asia.”

First author on the paper describing the study, Associate Professor Kathryn Holt from the University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute, said the study shows the Beijing lineage of TB bacteria spreads more easily from person-to-person than other strains of the bacteria. “Contact tracing – looking for early signs of TB infection in people who have been in close contact with TB patients, and treating them before they can spread the disease further – is an important part of TB control, but it takes a lot of resources,” said Associate Professor Holt. “All TB patients have the potential to transmit the TB bacteria to others when they cough, but our data indicates this is more likely to result in new disease cases if the infection is caused by the Beijing lineage. So if resources are limited, it would make sense to prioritise contact tracing for Beijing lineage TB cases.”

Co-author Dr Nguyen T. T. Thuong, head of OUCRU’s TB group in Ho Chi Minh City, comments: “TB treatment fails in many patients infected with multidrug resistant strains, which are then passed on, increasing the number of resistant cases in the community. My team in Vietnam now is running a pilot study in early diagnosis of drug resistant TB cases using whole genome sequencing. The findings from this publication can be applied concurrently to identify those carrying the easily-spread-mutation. If this test becomes a bedside diagnostic tool, it will allow not only early diagnosis of drug resistance and more precise treatment but also better management against disease transmission.”

The study was funded by the National Health and Medical Research Council in Australia, Wellcome Trust UK and A*STAR Biomedical Research Council Singapore.

Similar stories

We gathered rich insights into child survival in Kenya by mapping patterns over 22 years

KWTRP Research

Although improvements in child survival globally have been remarkable, 5.2 million children still died in 2019, over half of these in sub-Saharan Africa. A range of factors likely include disparities in childhood immunisations, supplements and breastfeeding practices, antenatal care, skilled birth attendants working in healthcare facilities. Kenya needs to prioritise its child care plans, based on localities and populations with the greatest need. Two KWTRP studies give granular insights into the situation in regions across Kenya.

How Nepal can survive a second COVID wave

OUCRU OUCRU-Nepal

Nepal is seeing a COVID surge that is proportionately similar to India. While we try to treat the sick by increasing hospital space and ensuring oxygen supply, we must also plan for an exit strategy. Over-preparation rather than under-preparedness needs to be our mantra, with widespread vaccination the key to get us out of this pandemic, by Professor Buddha Basnyat

Supporting children to grow smarter, not just taller

EOCRU OUCRU

Anuraj Shankar from our EOCRU unit in Jakarta, Indonesia, with Elizabeth Prado and Leila Larson describe a meta-analysis showing that responsive caregiving boosts infants’ brain development. Parenting group sessions and home visits improve cognitive, language, and motor skills. And nutrition-only programmes have much less effect than comprehensive interventions.

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.